Method and apparatus for determining chemical states of living animal or human tissue using nuclear magnetic resonance

• US 5,318,031 A
• Filed: 05/19/1992
• Issued: 06/07/1994
• Est. Priority Date: 07/23/1990
• Status: Expired due to Term

• Current Assignee: MS Cognosis Pty., Limited
• Original Assignee: Bruker Analytische Messtechnik GmbH
• Inventors: Russell, Peter, Mountford, Carolyn E.
• Primary Examiner(s): Smith, Ruth S.
• Application Number:
  US07/842,148
• Time in Patent Office: 749 Days
• Field of Search: 128/653.2, 436/64, 436/86, 436/173
• US Class Current: 600/410
• CPC Class Codes: G01R 33/465 applied to biological material, e.g. in vitro testing
• CPC Class Codes: Y10T 436/24 Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Abstract

In a method for determining chemical states of living animal or human tissue using nuclear magnetic resonance with a homogeneous constant magnetic field, the tissue is measured by means of a high-resolution nuclear magnetic resonance measurement and the measured values obtained are then evaluated by comparison with measured values from resonance measurements on comparable tissue to determine whether the chemical state of the tissue corresponds to a chemical normal state or to a deviating abnormal state. In order to enable a determination of chemical intermediate states to be made, it is proposed to compare the measured values obtained with such a series of reference measurements which also contain the detectable characteristic transition states between the chemical normal state and the abnormal end state and that the chemical transition state of the measured tissue sample is determined from the comparison.

Claims

1. Method for determining chemical states of living animal or human tissue using nuclear magnetic resonance with a homogeneous constant magnetic field, the tissue being measured by means of a nuclear magnetic resonance measurement and the measured values obtained then being evaluated by comparison with measured values from reference measurements on comparable tissue to assess whether the chemical state of the tissue corresponds to a chemical normal state or to a deviating abnormal end state, wherein the measured values obtained are compared with such a series of reference measurements which also contain detectable characteristic transition states between the chemical normal state and the abnormal end state, and wherein the chemical transition state of the measured tissue sample is determined from the comparison.

2. Method as claimed in claim 1, wherein the tissue is measured using a high-resolution, two-dimensional, scalar correlation spectroscopy (2D-COSY), nuclear magnetic resonance measurement, and the measured values obtained are compared with a series of reference values for chemical transition states of corresponding tissue.

3. Method as claimed in claim 2, wherein at least one characteristic cross-peak is selected as criterion for the comparison between actual measured values for the tissue and the series of reference measured values and it is then determined whether or not the at least one cross-peak is present.

4. Method as claimed in claim 3, wherein the tissue is irradiated frequency-selectively with one or more high-frequency pulses P₁ generating transverse magnetization, during a high-resolution two-dimensional nuclear magnetic resonance measurement of the tissue, the band width of the high-frequency pulse comprising at least the resonance frequency of a molecule characteristic for a chemical transition state.

5. Method as claimed in claim 4, wherein on carrying out the nuclear magnetic resonance measurement, after radiation of the first high-frequency pulse P₁ generating the transverse magnetization, and before a pulse P₃ used for a measurement of the free induction decay FID is radiated, further 180°

high-frequency pulses P₂ '"'"' are radiated in a number until, concerning undesired signals, the condition

m·

t_e >

T₂ is met, where

m is the number of further high-frequency pulses P₂ '"'"',

t_e is the spin echo evolution time, and

T₂ is the transverse relaxation time of the undesired signals.

6. Method as claimed in claim 5, wherein the chemical transition states between normal state and deviating end state are subdivided into the groups non-critical, dubious and pre-malignant states, and the corresponding measured values for the reference measurements are assigned to these groups of states so that on comparison of the measured values obtained for the measured tissue sample an allocation to a group of pre-defined chemical transition states is obtained at the same time.

7. Method as claimed in claim 6, wherein those values which correspond to chemical intermediate states of the tissue which originate from chemical changes which are not directly involved in the direct chemical transformation process between the normal state and the abnormal end state, it being possible, however, for said changes to lead to the transformation process leading to the abnormal chemical end state, are added to the series of reference measured values.

8. Method as claimed in claim 7, wherein a tissue sample obtained by biopsy or a cell mass obtained by culture is subjected to the high-resolution nuclear magnetic resonance measurement in vitro.

9. Method as claimed in claim 8, wherein the evaluation is carried out on those cross-peaks in a 2D-COSY proton spectrum which correspond to the metabolites characteristic for the transformation process.

10. Method as claimed in claim 9, wherein a tissue sample from the neck of the uterus (cervix uteri) is used and wherein if cross-peaks of at least one of the amino acids isoleucine (Ile), leucine (Leu), valine (Val) and/or phenylalanine (Phe) are present in the tissue sample the chemical state thereof is assessed as "pre-malignant".

11. Method as claimed in claim 10, wherein evaluation is also carried out for cross-peaks which are assignable to lactate and wherein such a chemical state is classified as "early invasive" abnormal end state.

12. Method as claimed in one of claims 1 to 11, wherein a proton nuclear magnetic resonance measurement is carried out in which the H₂ O signal is suppressed by pre-saturation.

13. Method as claimed in claim 9, wherein evaluation is also carried out for cross-peaks which are assignable to lactate and wherein such a chemical state is classified as "early invasive" abnormal end state.

14. Method as claimed in one of claims 2 to 7, wherein the evaluation is carried out on those cross-peaks in a 2D-COSY proton spectrum which correspond to the metabolites characteristic for the transformation process.

15. Method as claimed in one of claims 1 to 6, wherein a tissue sample obtained by biopsy or a cell mass obtained by culture is subjected to the high-resolution nuclear magnetic resonance measurement in vitro.

16. Method as claimed in one of claims 1 to 5, wherein those values which correspond to chemical intermediate states of the tissue which originate from chemical changes which are not directly involved in the direct chemical transformation process between the normal state and the abnormal end state, it being possible, however, for said changes to lead to the transformation process leading to the abnormal chemical end state, are added to the series of reference measured values.

17. Method as claimed in one of claims 1 to 4, wherein the chemical transition states between normal state and deviating end state are subdivided into the groups non-critical, dubious and pre-malignant states, and the corresponding measured values for the reference measurements are assigned to these groups of states so that on comparison of the measured values obtained for the measured tissue sample an allocation to a group of pre-defined chemical transition states is obtained at the same time.

18. Method as claimed in one of claims 2 or 3, wherein on carrying out the nuclear magnetic resonance measurement, after radiation of the first high-frequency pulse P₁ generating the transverse magnetization and before a pulse P₃ used for a measurement of the free induction decay FID is radiated, further 180°

high-frequency pulses P₂ '"'"' are radiated in a number until, concerning desired signals, the condition

space="preserve" listing-type="equation">m·

t.sub.e >

T.sub.2

is met, where

m is the number of further high-frequency pulses P₂ '"'"',

t_e is the spin echo evolution time, and

T₂ is the transverse relaxation time of the undesired signals.

19. Method as claimed in claim 2, wherein the tissue is irradiated frequency-selectively with one or more high-frequency pulses, generating the transverse magnetization, during a high-resolution two-dimensional nuclear magnetic resonance measurement of the tissue, the band width of the high-frequency pulse comprising at least the resonance frequency of a molecule characteristic for a chemical transition state.

20. Apparatus for determining chemical states of living animal or human tissue using nuclear magnetic resonance, comprising a nuclear magnetic resonance spectrometer (12) for carrying out a nuclear magnetic resonance measurement on the tissue, computer means (16) for determining measured values for the nuclear magnetic resonance measurement on the tissue, means (24) for storing reference values of measurements on comparable tissue, means for comparing the measured values for actual measurement and reference measurement, and a computation means (22) connected to said means for comparing for making an assignment of the actual measurement to a chemical transition state based on a comparison of the measured values wherein the means (24) for storing reference values consist of a database which contains such a series of reference values for reference measurements which also comprise detectable characteristic transition states between the chemical normal state and the chemically abnormal end state.

21. Apparatus as claimed in claim 20, further comprising a memory (26) for storing a computation algorithm, a spectral data memory (20) and an output unit (28), wherein the computation means (22) is connected to the database (24) and to the memory (26) for a computation algorithm and computes the actual measured values supplied from the spectral data memory (20) and supplies the result to the output unit (28).

22. Apparatus as claimed in claim 21, further comprising a control unit (18), and wherein the computer means (16) is connected via the control unit (18) to the spectrometer (12), said computer means (16) also being connected to the computation means (22) and in series with the spectral data memory (20).

23. Apparatus as claimed in claim 22, wherein the spectrometer (12) contains a sample head (30) in order to measure an in vitro tissue sample.

24. Apparatus as claimed in one of claims 20 to 22, wherein the spectrometer has a sample receiver for receiving an animal or human body, and surface HF coils disposed within said receiver for surrounding a body received in said receiver and for facilitating an in vivo measurement.

25. Apparatus as claimed in one of claims 20 or 21, wherein the spectrometer (12) contains a sample head (30) in order to measure an in vitro tissue sample.